Robert J Mark

US Patent:

6664068, Dec 16, 2003

Filed:

Apr 4, 2002

Appl. No.:

10/116370

Inventors:

Robert Mark - Lawrenceville NJ
Kathleen H. Young - Newtown PA
Andrew T. Wood - Newtown PA

Assignee:

Wyeth - Madison NJ

International Classification:

G01N 3353

US Classification:

435 71, 530350, 53038822, 5303877, 4241301, 4241341

Abstract:

The present invention relates, at least in part, to polypeptides which include Bcl-xL binding domains, novel Bcl-xL binding domains of Pablo polypeptides, nucleic acid molecules encoding such polypeptides, and uses thereof. For example, such polypeptides and nucleic acid molecules are useful in modulating apoptosis, particularly in neural cells, as well as in the treatment or prevention of disorders that can benefit from modulation of cell death.

US Patent:

20020137049, Sep 26, 2002

Filed:

May 15, 2001

Appl. No.:

09/858155

Inventors:

Robert Mark - Lawrenceville NJ, US
Kathleen Young - Newtown PA, US
Andrew Wood - Newtown PA, US

Assignee:

American Home Products Corporation

International Classification:

C12Q001/68
C07H021/04
C12N009/64
C12P021/02
C12N005/06

US Classification:

435/006000, 435/226000, 435/069100, 435/325000, 435/320100, 536/023200

Abstract:

The present invention relates, at least in part, to polypeptides which include Bcl-xL binding domains, novel Bcl-xL binding domains of Pablo polypeptides, nucleic acid molecules encoding such polypeptides, and uses thereof. For example, such polypeptides and nucleic acid molecules are useful in modulating apoptosis, particularly in neural cells, as well as in the treatment or prevention of disorders that can benefit from modulation of cell death.

US Patent:

20030215852, Nov 20, 2003

Filed:

Mar 24, 2003

Appl. No.:

10/395740

Inventors:

Robert Mark - Lawrenceville NJ, US
Andrew Wood - Newtown PA, US
Kamalakar Gulukota - Hyderabad, IN

Assignee:

Wyeth - Madison NJ

International Classification:

A61K048/00
C07K014/705
A61K038/17
C12Q001/68
C07K016/28

US Classification:

435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 530/388100, 514/012000, 514/044000, 536/023500

Abstract:

This invention relates to newly identified human pancortin polypeptides, the interaction of the pancortin polypeptides with a Pablo polypeptide, the use of such polypeptides, as well as the production of such polypeptides. The invention relates also to identifying compounds which modulate the activity of a pancortin polypeptides and/or the interaction of a pancortin-Pablo polypeptide interaction, wherein modulators can be agonists, antagonists and/or inhibitors of pancortin and/or the pancortin/Pablo interaction and therefore potentially useful in therapy.

US Patent:

20040157327, Aug 12, 2004

Filed:

Jun 23, 2003

Appl. No.:

10/601492

Inventors:

Robert Mark - Lawrenceville NJ, US
Kathleen Young - Newtown PA, US
Andrew Wood - Newtown PA, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K048/00
C07H021/02

US Classification:

435/375000, 514/044000, 536/023100

Abstract:

The present invention relates, at least in part, to polypeptides which include Bcl-xL binding domains, novel Bcl-xL binding domains of Pablo polypeptides, nucleic acid molecules encoding such polypeptides, and uses thereof. For example, such polypeptides and nucleic acid molecules are useful in modulating apoptosis, particularly in neural cells, as well as in the treatment or prevention of disorders that can benefit from modulation of cell death.

US Patent:

20060088912, Apr 27, 2006

Filed:

Jul 13, 2005

Appl. No.:

11/180855

Inventors:

Gouying Yan - Lexington MA, US
Yuhong Xie - Chestnut Hill MA, US
Janet Paulsen - Londonderry NH, US
Jimin Zhang - Chestnut Hill MA, US
Dionna Rookey - Philadelphia PA, US
Brian Bates - Chelmsford MA, US
Zhijian Lu - Bedford MA, US
Robert Mark - Lawrenceville NJ, US
Susie Campos - Hackettstown NJ, US

Assignee:

WYETH - Madison NJ

International Classification:

C12P 21/06
C07H 21/04
C12N 5/06
C07K 14/47

US Classification:

435069100, 435455000, 435358000, 530395000, 536023500

Abstract:

The present invention provides compositions and methods useful for purifying recombinant myelin-associated glycoprotein (MAG) and fragments thereof. In particular, the invention provides a one-step purification method for MAG and MAG fragments. Novel forms of human recombinant MAG protein are also disclosed in addition to methods of reliably producing and storing stable recombinant MAG proteins.

US Patent:

20070111929, May 17, 2007

Filed:

Aug 23, 2006

Appl. No.:

11/508441

Inventors:

Chad Beyer - Newtown PA, US
Robert Mark - Lawrenceville NJ, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 48/00
A61K 38/22
A61K 38/12

US Classification:

514009000, 514012000, 514044000

Abstract:

Methods for the treatment of neuropsychiatric disorders such as anxiety are disclosed. The methods involve modulating the expression of the angiotensin IV receptor or modulating the biological activity of the angiotensin IV receptor by utilizing antagonists to the receptor. Also disclosed are methods for identifying antagonists of the angiotensin IV receptor that are effective to reduce anxiety in a subject.

US Patent:

20100113415, May 6, 2010

Filed:

May 28, 2009

Appl. No.:

12/473773

Inventors:

Hemaka A. Rajapakse - Wyncote PA, US
Keith P. Moore - Harleysville PA, US
Philippe G. Nantermet - Lansdale PA, US
John M. Sanders - Collegeville PA, US
Sophie Parmentier-Batteur - Ambler PA, US
Robert J. Mark - Lawrenceville NJ, US

International Classification:

A61K 31/4745
C07D 471/04
C07D 413/14
A61K 31/437
A61K 31/5377
A61K 31/397
A61P 25/00

US Classification:

51421021, 546 82, 546119, 544127, 546 64, 514293, 514303, 5142342, 514287

Abstract:

The present invention is directed to compounds of generic formula (I)which are inhibitors of ephrin A4. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases regulated by the EphA4 RTK signaling, such as neurological and neurodegenerative disorders and cancer.